Intravesical Ozone Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMedipol University
This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of intravesical ozone therapy in 60 patients with interstitial cystitis (IC). Participants were assigned to ozone therapy, placebo, or standard care groups for 3 weeks, with follow-up at 6 weeks. The primary outcome was the change in O'Leary-Sant ICSI score. Secondary outcomes included VAS pain score, SF-36 physical health, and urinary frequency.
Age 18-65 years
Histopathologically or clinically confirmed IC (per AUA guidelines)
Symptoms for at least 6 months
Willing to provide informed consent
Active urinary tract infection
Bladder malignancy
Pregnancy or breastfeeding
Known ozone allergy